LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! We never stop scouting for new weapons to fight this battle. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 3 […]
Research presented during ASCO GU 2026, showed that germline DDR variants are common enough in metastatic prostate cancer to matter clinically, but their impact is highly gene-specific. In this 3,005-patient cohort, about 9% carried a germline DDR variant, and the study was especially important because it assessed both small variants and structural variants across 31 […]
Researchers at USC have found that prostate cancer cells may rely on a 3D network of DNA “switches”, called enhancers, to keep cancer genes turned on. Enhancers are not genes themselves; they are stretches of DNA that help control when nearby or distant genes are active and how strongly they are expressed. In this study, […]
VIR-5500 expanded into mHSPC in April 2026, when it announced the first patient had been dosed in the Phase 1 dose-expansion cohorts. VIR-5500 is being studied in late-line mCRPC as monotherapy and, importantly for this expansion, in combination with an androgen receptor pathway inhibitor in early-line mCRPC and mHSPC. The move was built on earlier […]
A very interesting Phase 1/2 trial of SL‑28 has started enrolling up to 60 patients with advanced solid tumours at The Southern Oncology Clinical Research Unit (SOCRU). Although the study is open to a broad range of solid cancers, it is particularly noteworthy for prostate cancer because a published case report described a complete response […]
EvoPAR‑Prostate05 is a Phase 3 maintenance trial testing the PARP1‑selective inhibitor saruparib (AZD5305) in men with metastatic hormone‑sensitive prostate cancer (mHSPC). The trial enrolls both HRR‑mutated and non‑HRR‑mutated patients but requires that each participant has confirmed homologous recombination repair mutation status (HRRm – genes such as BRCA1, BRCA2, ATM, PALB2, CDK12, RAD51B/C/D, or BARD1), homologous […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! New weapons on the way! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. I tried a different approach for this podcast, with more […]
The OPTIMAL-e trial is a phase 2 pilot study testing adaptive, PSMA-PET–guided radioligand therapy (RLT) with 177Lu-DOTA-HYNIC-panPSMA (TLX597-Tx) in men with metastatic hormone-sensitive prostate cancer (mHSPC), on top of standard androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI). Conducted at St Vincent’s Hospital in Sydney, it is single-arm, open-label, and nonrandomized, designed […]
Prostate cancer usually responds poorly to immunotherapy because the tumor hides from the immune system, earning the label of an “immune‑cold” cancer. A new RNA‑targeted CRISPR technology developed at Duke University School of Medicine and collaborating institutions re‑exposes these tumors to immune attack in mice by restoring a key protein complex on cancer cells that […]
SHY-ONC6 is now entering a Phase 1 first-in-human clinical study in patients with advanced or metastatic solid tumors. The trial is open-label and multicenter, and its main goals are to assess safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity in people whose disease has progressed on standard therapy or who cannot tolerate it. SHY-ONC6 […]